799 results on '"Gisslén, Magnus"'
Search Results
2. Reply to ‘Cognitive criteria in HIV: greater consensus is needed’
3. Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trial
4. Neurosyphilis is characterized by a compartmentalized and robust neuroimmune response but not by neuronal injury
5. The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based study
6. Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial
7. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19
8. Cerebrospinal fluid soluble CD30 elevation despite suppressive antiretroviral therapy in individuals living with HIV-1.
9. Herpes zoster in HIV-1 infection: The role of CSF pleocytosis in secondary CSF escape and discordance.
10. A comprehensive characterization of patients diagnosed with post-COVID-19 condition in Sweden 16 months after the introduction of the International Classification of Diseases Tenth Revision diagnosis code (U09.9): a population-based cohort study
11. Prophylaxis and treatment of HIV infection in pregnancy, Swedish guidelines 2024
12. IgG and kappa free light chain CSF/serum indices: evaluating intrathecal immunoglobulin production in HIV infection in comparison with multiple sclerosis
13. COVID-19 in people aged 18–64 in Sweden in the first year of the pandemic: Key factors for severe disease and death
14. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
15. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals
16. Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders.
17. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection
18. TTCOV19: timing of tracheotomy in SARS-CoV-2-infected patients: a multicentre, single-blinded, randomized, controlled trial
19. Comparison of SARS-CoV-2 spike RNA sequences in feces and nasopharynx indicates intestinal replication
20. Loss of Y in leukocytes as a risk factor for critical COVID-19 in men
21. The ratio of cardiac troponin T to troponin I may indicate non-necrotic troponin release among COVID-19 patients
22. Intensive care unit-acquired infections more common in patients with COVID-19 than with influenza.
23. Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?
24. A capture–recapture-based ascertainment probability weighting method for effect estimation with under-ascertained outcomes
25. COVID-19 Outcomes and Vaccinations in Swedish Solid Organ Transplant Recipients 2020–2021: A Nationwide Multi-Register Comparative Cohort Study
26. Surveillance of wastewater revealed peaks of SARS-CoV-2 preceding those of hospitalized patients with COVID-19
27. No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau)
28. Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy
29. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
30. Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment
31. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study
32. Alterations in glutamate, arginine, and energy metabolism characterize CSF and plasma metabolome of persons with HIV-associated dementia
33. COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients With Neurocognitive Post-COVID Complications
34. Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection
35. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1
36. Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection
37. COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial
38. Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis
39. Evolving Character of Chronic Central Nervous System HIV Infection
40. Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients
41. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.
42. Alterations in glutamate, arginine, and energy metabolism characterize cerebrospinal fluid and plasma metabolome of persons with HIVassociated dementia.
43. Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.
44. Body mass index and fitness in late adolescence and risk of cardiovascular disease, respiratory disease, and overall death after COVID‐19.
45. BMI and fitness in late adolescence and risk of cardiovascular disease, respiratory disease, and overall death after COVID‐19
46. The Swedish COVID-19 approach: a scientific dialogue on mitigation policies
47. Structural Brain Abnormalities in Successfully Treated HIV Infection : Associations With Disease and Cerebrospinal Fluid Biomarkers
48. CSF biomarkers in patients with COVID-19 and neurological symptoms: A case series
49. Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection
50. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.